Pfizer drops its B7-H4 conjugate
Felmetatug vedotin’s exit could be bad news for Mersana.
AstraZeneca doubles down on GPC3
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
The month ahead: February’s upcoming events
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
FDA red and green lights: January 2025
AstraZeneca bags three of the month’s four oncology approvals.
Pivotal study designs revealed
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
Cargo can't replicate firi-cel's academic success
Firce-1 is scrapped after showing dismal response rates and patient deaths.
